Key Highlights

● EyePoint Pharmaceuticals rebounded roughly 12% as bargain hunters and reassessing bulls stepped back into the stock.

● The bounce came one day after a violent selloff.

● EyePoint's LUGANO trial was the first of two pivotal Phase 3 studies evaluating DURAVYU, a vorolanib intravitreal insert, in wet age-related macular degeneration.

● The trial missed its primary endpoint, triggering the initial sharp decline before the current rebound.

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) rebounded roughly 12% as bargain hunters and reassessing bulls stepped back into a stock that had just been cut down by a disappointing Phase 3 readout. The bounce came one day after a violent selloff, and it reframed a complicated data set that was neither a clean win nor a total failure.

Why the Stock Is Surging

The surge is a rebound, not a breakout. According to trading coverage, EYPT crashed about 69% to $4.57 on August 17, 2026, after the topline results from the LUGANO Phase 3 trial, then bounced about 10% on August 18 to recover toward $5.38 intraday. The task-cited 12% move fits this snap-back off deeply oversold levels.

The bull argument driving the bounce rests on the nuance in the data. LUGANO missed its primary vision endpoint on the full dataset. But EyePoint reported that when a small asymmetric cohort, roughly 4% of patients who suffered unrelated vision loss, was excluded, DURAVYU demonstrated non-inferiority to aflibercept, the standard-of-care comparator. Secondary outcomes were described as strong, including a reported 42% reduction in treatment burden, high supplement-free rates and a favorable safety profile. Bulls seized on the durability angle as the reason the story is not over.

What Happened

EyePoint's LUGANO trial was the first of two pivotal Phase 3 studies evaluating DURAVYU, a vorolanib intravitreal insert, in wet age-related macular degeneration (wet AMD). Missing the primary endpoint on the full population is a serious setback for any registrational program, and the market's initial reaction was severe.

The subsequent rebound reflected a second read of the details rather than any new disclosure. Analysts largely maintained bullish ratings while trimming price targets, according to the coverage reviewed, with JPMorgan the notable exception, downgrading to Neutral after the crash. That split, most staying constructive, one stepping aside, captures how genuinely divided opinion became.

On the financial side, EyePoint reported second-quarter Revenue of about $507,000 and a per-share loss of roughly $(1.09), with Negative cash flow near $(63.5) million but a cash balance of about $110.6 million, which the company has said provides runway to fund continued development.

Why Investors Are Paying Attention

Wet AMD is a large, chronic market, and the central problem for patients and physicians is treatment burden: standard anti-VEGF therapies often require frequent intravitreal injections. A product that maintains vision outcomes while meaningfully reducing how often patients need treatment would address a real pain point.

That is why the reported 42% reduction in treatment burden matters to bulls even after a missed primary endpoint. If regulators and physicians ultimately view DURAVYU as offering comparable vision with far fewer injections, the durability narrative could still support a commercial path. The stock's whipsaw reflects a market trying to price exactly how much weight to give the adjusted analysis versus the headline miss.

What the Company Does

EyePoint Pharmaceuticals develops and commercializes therapies for serious eye diseases, with a focus on sustained intraocular drug delivery. Its lead clinical asset, DURAVYU, uses the company's insert technology to deliver vorolanib, a tyrosine kinase inhibitor, inside the eye over an extended period. The strategic aim is to reduce injection frequency for conditions such as wet AMD and diabetic macular edema (DME) while preserving efficacy.

The Bull Case

Bulls argue the market overreacted to the headline. If the excluded asymmetric cohort truly reflects unrelated vision loss, the adjusted non-inferiority result and strong secondary endpoints could still underpin a viable regulatory and commercial story built on durability. The reduction in treatment burden speaks directly to an unmet need.

They also point to upcoming catalysts. The second pivotal wet AMD study, LUCIA, is fully enrolled with topline data expected in the fourth quarter of 2026, and a potential DURAVYU NDA submission could follow in the first half of 2027, with DME Phase 3 readouts anticipated in 2027. A clean LUCIA result would go a long way toward rehabilitating the program. A cash balance north of $110 million provides runway to reach those milestones.

Risks

The risks are equally clear. A missed primary endpoint is a missed primary endpoint, and regulators may not accept an analysis that excludes patients post hoc. If the FDA is unpersuaded, the path to approval narrows sharply. The 69% one-day crash shows how unforgiving the market can be, and the rebound could prove fragile if sentiment sours again.

The entire durability thesis now hinges heavily on LUCIA. A second miss would be devastating for the program and the stock. EyePoint also burns cash rapidly, negative Operating Cash Flow near $(63.5) million in the quarter, which raises the specter of future dilution even with a healthy current balance. Competition in wet AMD is intense, with entrenched anti-VEGF standards of care.

What Investors Should Watch Next

● LUCIA Phase 3 topline data, expected in the fourth quarter of 2026, the pivotal make-or-break catalyst.

● Any FDA feedback on whether the adjusted LUGANO analysis supports a regulatory filing.

● Timing and viability of a potential DURAVYU NDA submission in the first half of 2027.

● Analyst rating and price-target revisions as the data are digested.

● Cash runway and any signs of a Capital raise given the elevated burn rate.

A Bounce Following a Painful Selloff

EyePoint's roughly 12% bounce is a rebound from a catastrophic drop, driven by investors reweighing a genuinely mixed LUGANO readout rather than by fresh good news. The primary endpoint miss is real and cannot be waved away, but the durability signals, non-inferiority in the adjusted analysis and a sharp cut in treatment burden, give bulls a thesis to defend. The stock is now a binary bet on the LUCIA readout later this year and on how regulators view the data. Expect continued Volatility until that clarity arrives.